"The approval and launch of this therapeutic breakthrough into overseas markets brings a new option to those millions of people that suffer from health issues related to toxic digestive tracts. We are extremely pleased to introduce Colopril to them. The product has already been widely used by consumers in North America. Today's announcement is a unique and rare moment in the supplement industry as it shows that products like Colopril are going to make a huge positive impact on the health improvement of global consumers. We have already seen the positive reception that the product has garnered through the U.S. media and the response has been quite clear that Colopril is a product that works. We are bracing ourselves for this product to fly off the shelves" said Cathy Sheridan, Marketing Director North America.
One of the most talked about and sought after colon detoxifying products available today, Colopril has been scientifically formulated to promote gentle and effective internal cleansing and detoxification while eliminating parasites and dangerous toxins. Colopril's precise combination of natural herbs and fibers will effectively balance and regulate your body for optimal health. The ground-breaking technology employed by the product is a blend of its' active ingredients in a proprietary formula.
Pharmaxa Laboratories develops and markets nutraceutical products for the treatment of gastrointestinal issues. Hamada's strategy is to in-license late-stage or marketed proprietary therapeutic supplements, complete any required development and regulatory submission of these products, and market them in the United States and Europe through the Company's specialty sales and marketing team.
More complete detailed product information and directions of use can be found on www.Colopril.com
Colopril Product Approved for International Sales Distribution


